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Abstract
Purpose Little is known about sociodemographic and clinical factors that predict and act as barriers to ADHD medication 
independently of symptom severity. We examined the proportion of children using medication for ADHD, age of initiation 
of medication, and predictors of medication use in a population-representative cohort.
Methods Data from the Millennium Cohort Study on child ADHD, medication use for ADHD at age 14 (in 2014–2015) and 
child, parent and sociodemographic variables were collated. Logistic regression models were used to identify factors that 
predict medication use for ADHD (the main outcome measure), adjusting for symptom severity at age seven.
Results The weighted prevalence of ADHD was 3.97% (N = 11,708). 45.57% of children with ADHD (N = 305) were tak-
ing medication. The median age at initiation was 9 years (range 3–14). Male gender (AOR 3.66, 95% CI 1.75, 7.66) and 
conduct problems at age seven (AOR 1.24 95% CI 1.04, 1.47) and 14 predicted medication use at age 14 after adjusting for 
symptom severity.
Conclusions Our study is the first to assess predictors of medication whist adjusting for ADHD symptom severity. Girls 
with ADHD were less likely to be prescribed medication, even when they displayed similar ADHD symptom levels to boys. 
Conduct problems also predicted medication independently of ADHD symptoms. ADHD may be more often medicated 
in boys because clinicians may think a prototypical ADHD child is male, and perhaps conduct problems make boys more 
disruptive in the classroom, leading to boys being more often treated.
Keywords ADHD · Gender · Pharmacology · Cohort · Epidemiology
Introduction
Barriers to accessing care for attention deficit/hyperactivity 
disorder (ADHD) have been studied at the levels of iden-
tification and referral to specialist services [1] where an 
assessment is made and diagnosis assigned. There is less 
knowledge of whether treatment decisions are predicted 
by sociodemographic or clinical characteristics. Social and 
cultural influences impact on what treatment recommenda-
tions are made, whether children receive the most appropri-
ate treatment [2] and also influence parents’ attitudes [3]. 
A recent systematic review identifies a group of “wider 
determinants” affecting access to care for ADHD operating 
at societal level including gender, age, ethnicity, socioeco-
nomic status (SES), social networks and urban residence. 
Factors that predict service utilisation include comorbid 
disorders, adult perceptions of problems and willingness to 
engage [4].
Existing evidence as to whether socio-cultural factors also 
operate as barriers and predictors to accessing pharmaco-
logical treatment for ADHD is mixed: some studies find no 
differences by gender [5–7], another reports that boys are 
more likely to be prescribed medication [8] and one finds 
that treatment initiation (both pharmacological and psycho-
therapy) is more common in boys than girls in East Asia, 
although not in central Europe [9]. Co-occurring disorders, 
particularly conduct and oppositional disorders, have also 
been reported to be associated with increased likelihood 
of ADHD medication [5, 7, 8, 10] as have intellectual dis-
ability [8] and lower cognitive ability [7]. Low SES and 
being of ethnic minority have been reported to be a barrier 
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to accessing medication or services [1, 5, 11, 12]. However, 
the evidence base is limited in that studies examining what 
predicts medication use do not typically adjust for ADHD 
symptom severity, meaning factors that act as barriers to 
medication, but which are also associated with symptom 
severity are conflated in the findings.
The current study explores child, parent, and sociodemo-
graphic predictors of medication use among children with 
ADHD in a UK population-representative cohort. Our aims 
were to estimate the proportion of children with ADHD in 
the UK who are treated with medication, and to examine 
barriers to and predictors of medication use for ADHD at 
age 14, controlling for ADHD symptom severity at age 
seven.
Methods
Study design and sample characteristics
The Millennium Cohort Study (MCS) is a longitudinal UK 
population-representative cohort of British children born 
between the 1st September 2000 and the 11th January 2002. 
Families were eligible if they received child benefit (a uni-
versal benefit with near 100% uptake at the time). Detail 
on MCS design and sampling is reported extensively else-
where [13–15]. The total number of families in the MCS 
was 19,244: the number responding at age 14 was 11,726. 
Weightings supplied by MCS are used to adjust for attrition, 
maintaining a sample representative of the UK population 
as a whole (see Missing Data).
Six waves of data collection have been conducted: when 
children were aged 9 months, 3, 5, 7, 11, and 14 years. At 
each wave information on a range of social, economic, and 
health topics was collected through structured interviews at 
the family home, and on occasion via teachers in schools. 
Cognitive assessments and other data were also collected.
All participants of the MCS provided informed consent 
and the main study had full ethical approval in place. Ethical 
approval for the current analysis was given by the University 
of Exeter College of Social Sciences and International Stud-
ies Ethics Committee (ref 201718-093).
Measures
Child ADHD (yes/no). Parents were asked “Has a doctor 
or health professional ever told you that [child’s name] has 
had any of the following problems: attention deficit/hyper-
activity disorder (ADHD)?” The child was classed as having 
ADHD if the parent responded in the affirmative at when the 
child was aged seven, 11 or 14. This question was based on 
the wording used by US National Health Interview Survey 
(NHIS) and National Survey of Children’s Health, which has 
been widely used to estimate prevalence of ADHD [5, 16] 
and Autism Spectrum Disorders [17].
Outcome: ADHD medication (yes/no). When children 
were age 14, parents who had reported their child had 
ADHD were asked “Is [child’s name] currently taking any 
medicines on a regular basis that were prescribed by a doc-
tor or hospital for their ADHD?” A list of licensed ADHD 
medications was also provided, that included methylpheni-
date, dexamphetamine and atomoxetine.
Age at medication initiation: Those who indicated that 
their child was taking medication were asked “How old was 
[child’s name] when [he/she] was first prescribed these 
medicines?” Three responses of two years old and younger, 
and ‘don’t know’ were classified as missing as no ADHD 
medication is licensed for children under the age of three 
in the UK.
ADHD symptom severity: the Strengths and Difficulties 
Questionnaire (SDQ) [18]; a widely used and validated 
behavioural screening questionnaire, was completed by par-
ents and teachers when the child was seven. The SDQ has 
a sensitivity of 89% and specificity of 78% for the subscale 
pertaining to ADHD in comparison with clinical diagnosis 
[19], and has satisfactory internal consistency (Chronbach’s 
α) of 0.49 in a UK sample [20]. The hyperactivity/inattention 
subscale (SDQ-H/I) is comprised of five questions distrib-
uted across the 25-item SDQ, and asks about the frequency 
of five behaviours common in ADHD covering inattention, 
impulsivity and hyperactivity. It is scored from 0 to 10 with 
higher scores indicating greater difficulties. Although the 
SDQ is more brief than other measures commonly used to 
assess ADHD, such as the Child Behaviour Checklist, it cor-
relates highly with these more extensive measures [21]. An 
algorithm generating unlikely, possible and probable diagno-
sis of ADHD [19] was utilised to capture symptom severity: 
this combined both parent and teacher report of SDQ-H/I 
symptoms and their impact. This algorithm has been found 
to have a sensitivity of 75% for parent and teacher ratings 
combined [22] and has a high level of agreement with inde-
pendent clinical diagnosis [19].
Predictors of ADHD medication use
Child‑based characteristics
Predictors comprised child gender, cognitive ability at age 
three (score on the Bracken School Readiness Assessment, 
administered individually by computer [23]), and conduct 
problems. The SDQ conduct problems (SDQ-CP) score 
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sums the responses from five items that ask about temper, 
anger and antisocial behaviour. Parent and teacher ratings of 
conduct problems at age seven were included as predictors 
of medication use: scores were treated as continuous with a 
range from 0 to 10. As conduct problems tend to occur later 
in childhood we also included parent-reported SDQ-CP at 
age 14.
Parent characteristics
Mother report of ever being diagnosed with depression or 
anxiety at the child age seven wave (yes/no), and mother 
and father report of having a mental health or social/behav-
ioural condition including autism or ADHD (yes/no) were 
included as predictors. Maternal age at child’s birth (years), 
and smoking during pregnancy (number of cigarettes per 
day) were also included.
Sociodemographic characteristics
Characteristics measured at the 9 month wave were eth-
nicity (white British or other) and maternal education (no 
qualifications; secondary school; degree or higher). When 
the child was seven the remaining predictors were captured: 
family size (no siblings; one; two; or > two siblings), single 
parent family (vs two parents), family weekly income (in £, 
adjusted for number of adults and children in the household 
based on OECD scales for equivilisation), whether living in 
poverty (income ≤ 60% of the median household income for 
the UK population), and housing tenure in three categories 
(housing association; private rent; owned). We also provide 
descriptive statistics based on whether children were living 
in an urban or rural area at age 14, however, as this was cal-
culated differently across countries in the UK we have not 
analysed this further.
Analysis
The prevalence of ADHD by age 14 (parent-reported), over-
all and by gender was calculated relative to those who had 
responded in the negative to the ADHD diagnosis question. 
The proportion of children reported as having ADHD who 
used medication were described by gender and age of medi-
cation initiation. Descriptive statistics on predictors were 
generated showing the characteristics of children with medi-
cated ADHD, non-medicated ADHD, and, for comparison, 
the wider MCS cohort.
Logistic regression models were used to calculate the 
association between child, socioeconomic and parent pre-
dictors and ADHD medication use. Our comparison was 
between non-medicated children with ADHD and those tak-
ing medication. Unadjusted bivariate associations, expressed 
as odds ratios (OR) and 95% confidence intervals (95% CI) 
were reported. Following this, variables that were associated 
with ADHD medication with a p value of ≤ 0.10 were car-
ried forth into a multivariable regression model that adjusted 
for ADHD symptom severity. Continuous predictors (other 
than SDQ scores) were rescaled by dividing by two standard 
deviations, so that the strength of association was compa-
rable across continuous and binary predictors [24]. ORs, 
therefore, indicated the relative increase in odds of taking 
medication for ADHD, corresponding to a two standard 
deviation increase in the predictor. All analyses were car-
ried out in Stata v14.0 using the svy command and weights 
to adjust for sampling and attrition.
Missing data
At age 14, only 0.09% of ADHD diagnosis data were miss-
ing, 1.3% of those who were asked the medication ques-
tion did not provide a valid response. MCS study design 
accounted for attrition by over-sampling socioeconomically 
disadvantaged communities, then assessing drop-out at each 
time point. The MCS provides weights at each age point 
which account for drop-out in each sweep, keeping the sam-
ple representative of the UK population. Weights were gen-
erated using a logit model where the dependent variable was 
response/non-response, and included 12 variables predicting 
missingness. Weights were constructed and calculated based 
on the contribution of different sociodemographic predic-
tors to this regression model [25]. As such these weightings 
account for missing data due to attrition. For the current 
analysis, weighted prevalence estimates were calculated and 
regression models also adopted the appropriate weightings.
As the SDQ algorithm data were not complete (teacher 
data were missing for around half the sample) we conducted 
a sensitivity analysis adjusting for parent-reported SDQ-H/I 
score at age seven. This measure has been used in other stud-
ies as a measure of ADHD symptoms [26].
Results
Four hundred and seventy-one children were reported to 
have ADHD, which equated to a weighted prevalence of 
ADHD (N = 11,708) of 3.97% (95% CI 3.43, 4.60). Boys 
were five times more likely than girls to have ADHD (boys 
6.41%, 95% CI 5.45, 7.52; girls 1.29%, 95% CI 0.96, 1.74); 
Table 1.
305 parents of children with ADHD provided valid 
responses to the medication question at age 14. Under half 
(45.6%) of children with ADHD were taking medication at 
this age (N = 139); of these 11.5% were female and 88.5% 
male. The median age that medication was reported to have 
been first taken was 9 years old (range 3–14). Most reported 
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beginning to take medication during their primary school 
years (Fig. 1).
Table 2 shows characteristics of the sample both for chil-
dren with ADHD with and without medication, and for the 
wider cohort. Children with ADHD were more often male, 
had younger mothers, had lower SES and a higher propor-
tion of their parents reported mental health or social/behav-
ioural conditions (based on t tests for continuous or  chi2 
for categorical variables). There were insufficient responses 
from fathers about these conditions to allow analysis beyond 
a descriptive level. Children with ADHD displayed higher 
SDQ-CP and SDQ-H/I scores than children in the wider 
cohort. Further, children with ADHD who received medica-
tion were more likely to have higher parent-report SDQ-H/I 
scores at age seven than their ADHD peers who did not, 
although these symptoms were not rated as significantly 
more impactful. This resulted in a higher proportion of chil-
dren with ADHD who took medication being classified as 
‘probable ADHD’ by the ADHD symptom algorithm than 
those who did not.
Predictors of medication use for children with ADHD at 
age 14 are shown in Table 3. Children who were taking med-
ication were significantly more likely to be male (OR 3.37, 
95% CI 1.57, 7.23, p = 0.002), have higher levels of conduct 
problems at age seven (SDQ-CP parent OR 1.26, 95% CI 
1.09, 1.47, p = 0.002, SDQ-CP teacher OR 1.20, 95% CI 
1.02, 1.42, p = 0.03) and age 14 (OR 1.20, 95% CI 1.05, 
1.35, p = 0.003) and have mothers who reported smoking 
more cigarettes when pregnant (OR 1.60, 95% CI 1.10, 2.31, 
p = 0.01) in unadjusted regression models. White British eth-
nicity was associated with ADHD medication at p < 0.10, 
so this was taken forward into the adjusted model. After 
adjustment for symptom severity at age seven, male gender 
and parent-reported conduct problems at age seven and 14 
remained significantly associated with medication use at age 
14 (see Table 3). Males were more than three times as likely 
to receive medication. Each one point increase on the SDQ-
CP corresponded to a 24% increase in likelihood of ADHD 
medication at age 14. When repeating the adjusted models 
with the parent SDQ-H/I as an indicator of symptom severity 
instead of the SDQ algorithm, our findings remained almost 
identical (data available from lead author on request).
Discussion
Our study is the first we know of to assess predictors of 
medication whist adjusting for ADHD symptom severity. 
Girls with ADHD were less likely to be prescribed medica-
tion even when they display similar ADHD symptom levels 
to boys. Conduct problems also predicted medication inde-
pendently of ADHD symptoms, at both age seven and 14. 
Our findings show that these factors are important predic-
tors of ADHD medication, even when symptom severity is 
accounted for.
Existing studies have reported that 36–43% of children 
with ADHD in the UK are prescribed medication [1, 27, 
28]: lower than rates reported in Europe that range from 43 
to 67% [7, 10, 29]. Recent analysis conducted in the USA 
with similar methodology to the study we report here found 
that 62% of 2–17 year olds with current ADHD were taking 
medication in 2016 [5]. Rates of medication use in Canada 
have recently been estimated at 70% for those aged up to 
24 [6], and in East Asia 62% of young people with a new 
diagnosis of ADHD initiated pharmacological treatment in 
a 1-year observational study [9]. Existing studies that previ-
ous UK estimates derive from use small samples, primary 
care data or are over 10 years old: as such there is a need for 
further research in this area, especially given concern in the 
scientific literature and media about prescription rates for 
ADHD [30]. In the current study, 45.6% of children with 
ADHD were reported to be taking medication at age 14. 
The proportion of children with ADHD using medication 
remains lower than in North America, East Asia, France 
and Central Europe and in line with recent statistics from 
Germany (43.1% in 14 year olds in 2014) [5–7, 9, 10, 29].
As our data include only those who were taking medi-
cation at age 14 this may be an underestimate of the true 
prevalence of medicated ADHD as we would not capture 
those who discontinued prior to age 14. Having said this, 
prevalence of medication use for childhood ADHD has been 
Table 1  Prevalence of parent-reported ADHD: overall and by gender
Sample n Weighted % with 
ADHD
95% 
Confidence 
interval
All 11,708 3.97 3.43, 4.60
Female 5839 1.29 0.96, 1.74
Male 5869 6.41 5.45, 7.52
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
≤4 5 6 7 8 9 10 11 12 13 14
%
Child age (years)
Fig. 1  Age at medication initiation for children reported to be taking 
medication for ADHD
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Table 2  Descriptive statistics for ADHD children with and without medication, compared to a population sample
Note:  Age (years) refers to child age when data were collected: < 1 is the 9-month wave. ADHD: attention deficit/hyperactivity disorder. SD: standard 
deviation. SDQ: Strengths and Difficulties Questionnaire. CP: conduct problems subscale. HI: hyperactivity/inattention subscale ADHD severity at age 7 
was defined by the SDQ ADHD algorithm, including parent and teacher symptom and impact reports. Urban–rural dwelling based on office for national 
statistics codes (England and Wales), the Birkbeck urban–rural indicator (Northern Ireland) and the Scottish Executive urban–rural classification (Scotland)
Age (years) ADHD no medica-
tion (N = 166)
ADHD with medica-
tion (N = 139)
Rest of cohort 
(N = 18,938)
n n n
Child characteristics
Male (%) < 1 166 78.31 139 88.49 18,938 50.91
Cognitive ability, mean (SD) 3 129 43.26 (32.00) 108 45.68 (30.08) 13,604 56.81 (30.50)
SDQ-CP: parent, mean (SD) 7 141 2.77 (2.09) 121 3.86 (2.25) 13,131 1.36 (1.51)
SDQ-CP: teacher, mean (SD) 7 85 2.11 (2.08) 84 2.86 (2.33) 8562 0.74 (1.45)
SDQ-CP: parent, mean (SD) 14 159 3.22 (2.51) 137 4.44 (2.51) 11,032 1.35 (1.54)
Parent characteristics
Maternal age in years at childbirth, mean (SD) < 1 156 26.90 (6.01) 133 26.31 (5.66) 18,125 28.33 (5.96)
Number of cigarettes smoked daily in pregnancy, mean 
(SD)
< 1 157 3.22 (5.87) 133 5.35 (8.75) 18,241 2.00 (4.99)
Maternal depression/anxiety (%) 7 63 7.94 56 14.29 8439 6.61
Maternal mental health condition (% yes) 14 63 41.27 59 45.76 2667 29.36
Maternal social/behavioural condition, e.g., autism 
ADHD (% yes)
14 63 4.76 59 8.47 2667 2.70
Paternal mental health condition (% yes) 14 21 19.05 19 26.32 1461 14.78
Paternal social/behavioural condition, e.g., autism 
ADHD (% yes)
14 21 4.76 19 15.79 1461 2.67
Sociodemographic characteristics
White British (%) < 1 156 84.62 133 93.98 18,080 82.49
Maternal education
 No qualifications (%) < 1 156 20.51 134 27.61 18,194 19.46
 Secondary school (%) 60.26 61.19 56.27
 Degree or higher (%) 19.23 11.19 24.28
Family size
 Only child (%) 7 146 15.07 126 13.49 13,585 12.38
 1 Sibling (%) 38.36 41.27 44.84
 2 Siblings (%) 28.77 24.60 27.24
 More than 2 siblings (%) 17.81 20.63 15.55
Single parent family (%) 7 146 33.56 126 31.75 13,585 20.82
Family weekly income in £, mean (SD) 7 144 346.03 (230.15) 125 311.535 (192.78) 13,398 382.67 (227.60)
Below poverty line (%) 7 146 42.47 126 42.86 13,565 29.83
Housing tenure
 Social housing (%) 7 141 39.01  121 42.15 13,140 23.01
 Rent private (%) 15.6 12.4 8.76
 Home owner (%) 45.39 45.45 68.23
Urban dwelling (%) 14 126 90.48 146 89.04 13,583 86.91
Covariates
SDQ-HI parent (/10) 7 140 6.37 (2.96) 122 7.61 (2.44) 13,081 3.04 (2.47)
SDQ-HI teacher (/10) 7 85 6.35 (2.99) 84 7.04 (2.61) 8560 2.81 (2.76)
SDQ impact parent (/10) 7 141 1.97 (2.75) 121 2.58 (2.85) 12,978 0.27 (0.98)
SDQ impact teacher (/10) 7 68 1.78 (1.63) 71 2.25 (1.42) 7459 0.41 (0.97)
ADHD severity 7
 Unlikely ADHD (%) 141 48.23 125 33.60 13,162 91.64
  Possible ADHD (%) 39.72 42.40 7.04
  Probable ADHD (%) 12.06 24.00 1.31
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reported to peak at age 13–14 [29]: it will be of interest to 
explore whether the proportion of children in the MCS using 
medication subsequently decreases.
There were three peaks in age of medication initiation: 
at ages seven, nine and 12. At age seven, children in UK 
schools are subject to the first national tests. Consequently, 
there are increasing demands on cognition, behaviour 
and attention with children expected to remain seated and 
focussed [31]. The peak at age 12 corresponds to recently 
entering secondary school. The social and organisational 
demands of secondary schools are a large ‘jump’ from pri-
mary schools: children are expected to organise and bring 
their own study materials, and move from class to class 
throughout the day. It is likely that children with ADHD who 
could cope with demands at primary school level, where 
staff and location are consistent, may struggle more than 
their peers upon entry to secondary school [32] and medica-
tion may, therefore, become a viable option to enable chil-
dren to function at their best: indeed one of the major long 
term impacts of ADHD is poor educational attainment [33]. 
In addition at age 12 children are entering adolescence, and 
physical, emotional and mental changes associated with this 
may be linked to the initiation of medication.
We found medication was initiated at age three and four 
in a small number of children (4% of those who received 
medication). A larger proportion received medication at age 
five. Previous UK reports have been limited to children age 
six and above [34]. Early medication of children has been 
Table 3  Unadjusted and adjusted logistic regression models exploring predictors of ADHD medication use
Note: ADHD severity at age 7 was defined by the SDQ probable ADHD algorithm including parent and teacher symptom and impact reports. 
Predictors significant in unadjusted analysis were carried forward to the adjusted model. ADHD attention deficit/hyperactivity disorder, OR odds 
ratio, CI confidence interval, SDQ-CP Strengths and Difficulties Questionnaire, conduct problems subscale
Unadjusted Adjusted for age 7 ADHD severity
n OR 95% CI p n OR 95% CI p
Child characteristics
Male 305 3.37 1.57, 7.23 0.002 266 3.66 1.75, 7.66 0.001
Cognitive ability 237 1.41 0.77, 2.58 0.26
SDQ-CP: parent age 7 262 1.26 1.09, 1.47 0.002 262 1.24 1.04, 1.47 0.015
SDQ-CP: teacher age 7 169 1.20 1.02, 1.42 0.031 169 1.19 0.98, 1.45 0.080
SDQ-CP: parent age 14 296 1.20 1.07, 1.36 0.003 259 1.19 1.05, 1.35 0.006
Parent characteristics
Maternal age in years at childbirth 289 0.88 0.49, 1.58 0.66
Number of cigarettes smoked daily in pregnancy 158 2.35 1.14, 4.84 0.02 253 1.45 0.95, 2.23 0.09
Maternal depression/anxiety 119 3.20 0.72, 14.20 0.12
Maternal mental health condition 122 1.37 0.57, 3.30 0.47
Maternal social/behavioural condition, e.g., autism ADHD 122 1.58 0.38, 6.59 0.53
Sociodemographic characteristics
White British 289 2.68 0.98, 7.30 0.06 252 3.04 0.78, 11.77 0.11
Maternal education 290
 No qualifications ref
 Secondary school 0.79 0.46, 1.36 0.39
 Degree or higher 0.64 0.27, 1.53 0.32
Family size
 Only child 272  Ref
 1 Sibling 1.08 0.47, 2.47 0.86
 2 Siblings 0.81 0.33, 1.97 0.64
 More than 2 siblings 1.21 0.45, 3.22 0.70
Single parent family 272 0.92 0.53, 1.62 0.78
Family weekly income in £ 269 0.68 0.38, 1.22 0.19
Below poverty line 272 1.14 0.63, 2.04 0.67
Housing tenure
 Social housing 262 Ref
 Rent private 0.60 0.23, 1.58 0.30
 Home owner 0.85 0.48, 1.51 0.57
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a source of concern for ethicists [35] who have argued that 
very young children typically show inattention and hyper-
activity [36], thus it may not be appropriate. Alternately, it 
may be that children who are prescribed medication at such 
a young age comprise a group with severe symptoms that 
has led to family stress or exclusion from child care. Further 
research should explore this.
Many studies have found that more severe ADHD is 
associated with medication use [7, 9, 10, 27]. Gender also 
predicts more severe symptoms of ADHD [30]. We found 
that symptom severity was a powerful predictor of ADHD 
medication, with children who took medication suffering 
from more severe symptomology than those who did not. 
This finding aligns with clinical guidelines that suggest non-
pharmacological treatment should be the first line of treat-
ment for ADHD [37], so we would expect medication to be 
prescribed only for more severe cases.
Taking symptom severity into account, boys were over 
three times more likely to be taking medication for their 
ADHD than girls: a finding not seen in some other studies 
[5–7]. Treatment choice and decisions may be influenced by 
gender bias in beliefs about how likely the child is to ben-
efit from the treatment, and stigma operating differentially 
by child gender [4]. It could be that girls are perceived by 
parents, teachers or clinicians as less likely to benefit from 
pharmacological treatment or more likely to benefit from 
behavioural treatments: evidence in this area is lacking. Our 
study provides evidence that even if recognised, girls may 
face additional barriers to access treatment: clinicians should 
be aware of this. Alternatively, some have argued ADHD is 
too frequently diagnosed in boys, and that clinicians think a 
prototypical ADHD child is male. This might lead to boys 
being more often recognised and treated [38].
The second significant predictor of whether children 
received ADHD medication was conduct problems. The 
SDQ-CP subscale asks about temper, obedience, fighting, 
lying and stealing. Our finding is in line with other stud-
ies that report co-occurring conduct symptoms to be more 
frequent in those who receive medication for ADHD [5, 
7, 8, 10]. This raises debate as to whether medication for 
ADHD is being prescribed to those who display problem-
atic behaviour beyond ADHD, or whether those with the 
most severe or complex behavioural difficulties are taking 
medication because of this complexity. A moderator analy-
sis of the multimodal treatment for ADHD study found 
that children with comorbid conduct or oppositional defi-
ant disorder at baseline responded similarly to treatment 
to those without these comorbidities [39]: medication was 
not disproportionately beneficial to these children. How-
ever, a recent systematic review reports evidence that both 
psychostimulants and atomoxetine are effective in reduc-
ing disruptive and aggressive behaviours in children with 
ADHD [40]. Our findings raise questions about diagnostic 
silos and whether children with both ADHD and conduct 
disorder should be viewed through the ADHD or conduct 
disorder lens. If medications currently licensed to treat 
ADHD are beneficial for a primary diagnosis of conduct 
disorder, consideration of whether UK clinical guidelines 
and licensing should be changed is needed. The National 
Institute for Health and Care Excellence (NICE) ADHD 
guideline recommends non-pharmacological treatments 
as the first option for those with ADHD and symptoms of 
conduct disorder [37], however, guidelines from Canada 
and other countries recommend medication in these cases 
(e.g., [41, 42]). Clinicians should be aware that severity of 
problems in comorbid ADHD and conduct disorder may 
be driven by the latter. Monitoring treatment response is, 
therefore, essential to ensure medication is beneficial in 
these cases.
Although children with ADHD were of lower SES than 
the MCS cohort, no measure of SES was associated with 
ADHD medication use. This is encouraging as it suggests 
that the current system is free from bias in either direction: 
it has been argued that low SES may preclude individu-
als from medication access because of the affordability of 
medication, or stigma around the perceived cause of the 
child’s symptoms. As the UK healthcare system is free at 
the point of use, and prescriptions are free for those on low 
incomes, our results may reflect societal organisational 
structures that allow healthcare access equally to those 
from different socioeconomic backgrounds.
Previous studies [11, 43], found an association between 
medication and socioeconomic disadvantage, but reported 
opposing directions of effect. The study by Froehlich et al. 
using national survey data in the USA found low SES to 
be a barrier to medication use, whereas the Swedish reg-
ister-based study of Hjern et al. finds socioeconomic dis-
advantage to be a strong predictor of ADHD medication 
use. There appears to be an interaction between ADHD 
being more prevalent and severe in those who grow up 
in socioeconomically disadvantaged households [44] and 
the healthcare system in the country where the study is 
conducted. Our findings highlight that each healthcare 
system will have its own biases in prescribing practices 
and throw the status of low SES as a barrier to medication 
into question.
Strengths and limitations
The use of longitudinal cohort data is necessarily con-
strained by the range of data collected. Cohorts are not best 
suited for estimating prevalence due to the inevitable attri-
tion, although to an extent this is statistically accounted for 
by the sampling frame and weighting. Our case definition 
of ADHD was parent-report of whether they have been 
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told that their child has ADHD, and omits precise termi-
nology about diagnosis. Parent-report of ADHD diagnosis 
using terminology almost identical to that used in the MCS 
is considered appropriate for national estimates of ADHD 
prevalence in the USA [45]. The validity of parent-report 
of child medication for ADHD has been shown to be good, 
with > 80% agreement between parent-report and clinical 
records [46]. Studies that examine the validity of parent-
reported diagnosis are lacking, however.
We are unable to ascertain whether children who 
received a diagnosis of ADHD had this rescinded prior 
to age 14: our estimates are therefore of ever receiving 
a diagnosis, rather than current diagnosis at 14. Medica-
tion use and age of medication initiation was restricted to 
those who were currently taking medication at the age of 
14. Other children with ADHD may have used medica-
tion but discontinued this by the age of 14, or received a 
diagnosis of ADHD that did not persist to age 14. Despite 
these limitations, the proportion of children reported to 
have ADHD in MCS falls in line with current prevalence 
estimates [47]. A further limitation is that data on the type 
of medication being used was not collected.
The study also has strengths: a population-representa-
tive sample that has over 300 children with ADHD with 
pertinent longitudinal data, collected relatively recently. 
There were some missing data: parent mental health ques-
tions tended to be the least frequently answered (perhaps 
due to their sensitive nature), and teacher SDQs were 
not completed for all children. However, we considered 
it important to have a measure of symptom severity that 
did not solely rely on a parent informant, as ADHD must 
be present across settings, and conducted a sensitivity 
analysis using parent SDQ-H/I scores. Due to small sam-
ple sizes and occurrence of missing data, we did not have 
adequate power to explore whether some characteristics 
(such as paternal ADHD) were predictive of child ADHD 
medication use.
More work is required into whether children with con-
duct disorders are appropriately receiving medication for 
comorbid ADHD. Further exploration of predictors of 
medication use by medication type, and whether treat-
ment response is associated with any of these predictors is 
needed. Finally, further research should explore the other 
treatment options that children are being offered to man-
age their ADHD (e.g., [9]) as we are unable to ascertain 
what proportion of children were untreated or treated using 
psychosocial therapies.
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